— Know what they know.
/
Not Investment Advice

A

NYSE · USD
Agilent Technologies, Inc.
Healthcare · Medical - Diagnostics & Research
CEO Padraig McDonnell Employees 18,100 R&D / revenue 6.5%
Last price
$172.97−1.47%last session
Market cap
$48.8B
P/E (TTM)
34.0x
From 52w high
−2.5%
From 52w low
+59.6%
1-year return
+22.6%
RSI 14 · vs SMA200
62.4 · +28.6%
IS score
71.2/ 100
Factor model across 8 sub-scores, ranked against 3,010 US stocks. Describes the business, not the outlook.
Download full factsheet (PDF)

One year, rebased to 100

A   SPY   XLV (sector ETF) · weekly closes
8090100110120Jan 26Apr 26Jul 26Oct 26XLV 124A 123SPY 116

Score DNA

Each bar is a 0-100 score within the scored universe
74
Profitability
60
Growth
55
Value
82
Momentum
100
Risk (safety)
81
Quality
76
Balance sheet
74
Earnings quality

Flags

Strengths
None of the computed strength flags fires.
Warnings
None of the computed warning flags fires for A (Altman, Beneish, accruals, FCF, dilution).
Observations
Moat model: None, Efficient ScalePiotroski 7 / 9Altman Z 4.9Beta 1.242 of 4 smart-money sources active

Smart-money strip

Each disclosure source on its own window. Filings coinciding is not coordination.
INSForm 4 · 180 days
Insider open-market buys
0
2 open-market sales, $312,644
Form 144 notices (12m): 6, $3.2M proposed, not confirmed sales
CONGSTOCK Act · 180 days
Congressional purchases
0
No disclosed purchases
Members disclose in ranges, 30-45 days after the trade
13F13F · quarter to 2026-06-30
Net change in institutional holders
+56
146 new holders, 83 closed
1,126 filers hold 93.5% · 455 added, 355 trimmed
ETFETF holdings · 30 days
Net funds accumulating
+83
1,213 funds adding shares
1,130 funds trimming · counts of funds, not dollars
DARKFINRA · daily
Short-sale share of off-exchange volume
56.6%
20-day avg 45.3%, 50-day avg 51.0%
Latest 11.3 pp over its 20-day average · a flow, not short interest

Key financials · FY2025

USD, fiscal year. Stock-based compensation is non-cash; shown against FCF.
Income statement
Revenue$6.9B
Revenue growth YoY+6.7%
Gross margin52.4%
Operating income$1.5B
Operating margin21.3%
Net income$1.3B
Net margin18.8%
EPS (diluted)$4.57
Cash flow
Operating cash flow$1.6B
Capital expenditure$407.0M
Free cash flow$1.2B
FCF conversion (FCF / OCF)73.9%
Stock-based compensation$128.0M
FCF less SBC$1.0B
Buybacks$425.0M
Dividends$282.0M
Balance sheet & returns
Cash & short-term investments$1.8B
Total debt$3.4B
Net debt$1.6B
Shareholders' equity$6.7B
Goodwill & intangibles$4.9B
Debt / equity0.54
ROE (TTM)20.5%
ROIC (TTM)11.9%
Operating margin by fiscal year
21.3%FY202123.6%FY202219.8%FY202322.9%FY202421.3%FY2025
Revenue $6.3B (FY2021) to $6.9B (FY2025), a 2.4% CAGR.

Valuation

P/E (TTM)34.0x
EV / EBITDA25.0x
Price / sales6.62x
Price / FCF34.0x
FCF yield2.94%
Buyback yield0.87%
SBC / revenue1.8%
Price / book6.62x
Forward P/E FY202627.9x
Forward P/E FY202725.7x
Forward P/E FY202823.2x
Forward multiples divide today's price by Street EPS estimates. Street mean target $177.67 across 12 analysts last quarter is theirs, not ours.

A vs industry median

126 companies in Medical - Diagnostics & Research
Gross margin 53.7% 48.5% Operating margin 22.2% -9.4% Net margin 19.5% -9.5% ROIC 11.9% -2.5%
A (TTM)Industry median Asset turnover 0.53 vs industry 0.54 · financial leverage 1.90

Earnings delivery

Next report 2026-11-23 · consensus EPS $1.72
83%
beat rate, 10 of 12 quarters
+3.3%
median EPS surprise
7
longest beat streak
+3+6+3+5+4+2+4+0+0-1+6+9
EPS surprise in % vs the consensus at the time, oldest (left) to newest, 2023-11-20 to 2026-08-26. Bars cap at ±60%.

Peers

Market-cap band, not the industry cohort above
CompanyMkt capP/EROENet marginRev growth12m return
A Agilent Technologies, Inc. $48.8B34.0x20.5%19.5%+6.7% +22.6%
IDXX IDEXX Laboratories, Inc. $44.1B39.4x74.2%27.8%+12.8% −12.1%
IQV IQVIA Holdings Inc. $43.9B32.8x23.0%5.9%+8.2% +29.8%
WAT Waters Corporation $42.9B108.7x1.9%-8.3%+52.5% +30.5%
NTRA Natera, Inc. $56.7Bn/m-12.5%-8.9%+37.8% +117.9%
ILMN Illumina, Inc. $39.6B48.5x32.4%17.9%+4.9% —
MTD Mettler-Toledo International $32.5B36.4x-736.4%22.7%+6.9% —
DGX Quest Diagnostics Incorporat $25.9B24.6x14.4%10.5%+9.9% —
12-month window: SPY +15.9%, sector ETF XLV +24.2%. Past returns describe history only.

Recent 8-K filings

2026-09-08Officer/Director Change; Regulation FD; Exhibits
2026-08-26Earnings Release; Exhibits
2026-06-25Material Agreement; Financial Obligation; Exhibits
2026-05-27Earnings Release; Officer/Director Change; Exhibits
2026-05-04Officer/Director Change; Regulation FD; Exhibits
2026-04-06Officer/Director Change; Exhibits

Context

Shares outstanding281,965,815
Free float99.6%
Institutional ownership93.5%
Beta1.24
Dividend yield0.59%
Last dividend$0.26 on 2026-10-06
50 / 200-day average$158.26 / $134.32
Large-cap Healthcare median P/E29.7x

Full factsheet

The PDF carries everything on this page plus the cash-allocation waterfall, Form 144 notices, 13F holder detail, dark-pool and short-flow history, seasonality and the moat assessment (None).

Read it in the browser Download (PDF)

All fundamentals · 140 measures in 13 categories

Percentile = where A sits among 30 scored companies in Medical - Diagnostics & Research (0 = lowest value, 100 = highest). It is a position, not a grade.
ValuationProfitability (TTM)Returns on capitalGrowthMargin history & stabilityLiquidity (latest quarter)Leverage & solvency (latest quarter)EfficiencyCash flow & earnings qualityDividends & buybacksScores & forensic checksPer shareSize (TTM)

Valuation

MeasureAIndustry medianIndustry percentileSector median
P/E (TTM) 33.9x 35.5x
41st		 27.6x
PEG (P/E ÷ 3-yr EPS CAGR) 3.45 2.73
75th		 1.28
Price / sales 6.6x 5.7x
66th		 3.7x
Price / book 6.6x 4.1x
63rd		 3.6x
Price / tangible book 27.4x 9.0x
86th		 5.8x
Price / free cash flow 34.0x 34.4x
47th		 21.2x
Price / operating cash flow 30.3x 26.0x
61st		 17.1x
Enterprise value $51.0B $16.3B
86th		 $2.5B
EV / sales 6.9x 5.9x
66th		 3.8x
EV / EBITDA 25.0x 25.4x
43rd		 16.2x
EV / EBIT 28.9x 29.2x
47th		 23.0x
EV / free cash flow 35.5x 35.1x
53rd		 24.6x
Earnings yield 3.0% 1.7%
76th		 -0.3%
FCF yield 2.9% 2.5%
69th		 1.7%
Operating cash flow yield 3.3% 3.2%
52nd		 2.9%
Graham number (per share) $54.58 $65.89
41st		 $26.70

Profitability (TTM)

MeasureAIndustry medianIndustry percentileSector median
Gross margin 53.7% 52.9%
52nd		 65.1%
EBITDA margin 27.6% 15.0%
79th		 6.6%
Operating margin 22.2% 11.0%
86th		 3.5%
EBIT margin 23.9% 9.1%
86th		 2.4%
Net margin 19.5% 7.5%
86th		 0.3%
NOPAT margin 19.3% 9.5%
86th		 2.7%
FCF margin 19.5% 9.2%
76th		 4.3%
Operating cash flow margin 21.8% 15.0%
72nd		 7.1%
R&D / revenue 6.6% 7.2%
45th		 12.4%
SG&A / revenue 25.0% 29.8%
41st		 37.9%
Stock comp / revenue 1.8% 1.8%
46th		 4.5%
Effective tax rate 13.1% 20.5%
21st		 21.0%

Returns on capital

MeasureAIndustry medianIndustry percentileSector median
ROE (on average equity) 21.0% 4.7%
78th		 0.8%
ROA 11.0% 3.2%
83rd		 -0.3%
ROIC 14.9% 5.6%
83rd		 5.5%
ROCE 15.1% 4.0%
86th		 2.3%
Return on tangible assets 13.5% 3.5%
86th		 1.7%
Cash ROIC (OCF / invested capital) 16.8% 11.8%
69th		 9.7%
Gross profitability (GP / assets) 28.4% 22.3%
62nd		 29.9%
ROIC, 3-yr average 15.2% 3.7%
92nd		 2.6%
ROIC, 5-yr average 17.8% 5.7%
88th		 3.2%
ROE, 5-yr average 21.8% 3.1%
88th		 -4.9%
Incremental ROIC 23.7% -3.0%
67th		 17.2%

Growth

MeasureAIndustry medianIndustry percentileSector median
Revenue growth (TTM YoY) 8.6% 8.1%
57th		 10.5%
Revenue growth (QoQ) 2.3% 8.1%
17th		 7.2%
Revenue CAGR, 3 yr 1.8% 4.9%
33rd		 10.7%
Revenue CAGR, 5 yr 3.7% 7.0%
37th		 12.1%
Gross profit CAGR, 3 yr 3.6% 5.3%
41st		 10.6%
Operating income CAGR, 3 yr 5.1% 6.4%
47th		 11.7%
Net income growth (TTM YoY) 18.0% 11.8%
75th		 17.5%
Net income CAGR, 3 yr 8.3% 6.7%
75th		 11.3%
EPS growth (TTM YoY) 18.9% 15.1%
62nd		 19.2%
EPS CAGR, 3 yr 9.8% 9.3%
67th		 14.0%
EPS CAGR, 5 yr 9.5% -1.0%
71st		 8.1%
FCF growth (TTM YoY) 32.0% 12.4%
78th		 18.6%
FCF CAGR, 3 yr 0.4% 7.7%
14th		 15.4%
Operating cash flow CAGR, 3 yr -1.9% 8.0%
12th		 11.9%
Book value CAGR, 3 yr 11.4% 2.6%
80th		 2.1%
Dividend CAGR, 3 yr 2.1% 2.5%
20th		 2.2%
Sustainable growth rate 16.8% 10.3%
62nd		 12.2%

Margin history & stability

MeasureAIndustry medianIndustry percentileSector median
Gross margin, 3-yr average 53.7% 53.7%
50th		 62.6%
Operating margin, 3-yr average 22.1% 8.7%
89th		 1.0%
Net margin, 3-yr average 19.8% 4.1%
93rd		 -2.6%
FCF margin, 3-yr average 19.1% 10.5%
82nd		 3.2%
Revenue stability (0-1) 0.63 0.82
29th		 0.80
Earnings stability (0-1) 0.46 0.46
54th		 0.37
Margin stability (0-1) 0.97 0.93
82nd		 0.93

Liquidity (latest quarter)

MeasureAIndustry medianIndustry percentileSector median
Cash & short-term investments $1.8B $520.8M
90th		 $330.9M
Net cash (− = net debt) −$2.2B −$874.6M
31st		 $8.4M
Working capital $2.4B $404.8M
93rd		 $381.1M
Current ratio 2.05 2.13
48th		 3.02
Quick ratio 1.56 1.77
48th		 2.51
Cash ratio (cash + ST investments / current liabilities) 0.77 0.96
41st		 1.43
Defensive interval (days) 509 days 466 days
59th		 415 days

Leverage & solvency (latest quarter)

MeasureAIndustry medianIndustry percentileSector median
Total debt $3.9B $1.7B
79th		 $289.1M
Debt / equity 0.54 0.50
56th		 0.45
Net debt / equity 0.30 0.30
48th		 −0.13
Debt / assets 28.3% 28.5%
48th		 24.4%
Debt / capital 34.9% 33.6%
54th		 31.1%
Debt / EBITDA 1.94 3.30
29th		 2.62
Net debt / EBITDA 1.08 2.39
29th		 1.42
Interest coverage (EBIT / interest) 16.6x 2.9x
84th		 2.1x
Cash interest coverage 15.2x 6.7x
76th		 3.6x
Debt payback (years of OCF) 2.5 yrs 3.8 yrs
39th		 2.7 yrs
Liabilities / assets 47.3% 45.2%
52nd		 49.8%
IS credit model rating AA+ — —
Implied credit spread (bps) 65 175
3rd		 225

Efficiency

MeasureAIndustry medianIndustry percentileSector median
Asset turnover 0.56 0.56
52nd		 0.56
Fixed asset turnover 3.45 4.31
31st		 4.87
Inventory turnover 3.2 7.2
12th		 2.7
Receivables turnover 5.2 6.5
24th		 6.4
Days sales outstanding 71 days 56 days
76th		 57 days
Days inventory outstanding 114 days 51 days
88th		 136 days
Days payables outstanding 61 days 45 days
79th		 59 days
Cash conversion cycle (days) 124 days 67 days
86th		 70 days
Capex / revenue 2.3% 3.4%
24th		 2.6%
Capex / depreciation 0.64 0.69
41st		 0.55
Operating expense ratio 31.8% 45.1%
38th		 56.5%

Cash flow & earnings quality

MeasureAIndustry medianIndustry percentileSector median
Operating cash flow / net income 1.12 1.58
18th		 1.61
FCF / net income 1.00 1.14
24th		 1.36
FCF / operating cash flow 89.2% 76.8%
78th		 81.2%
Capex / operating cash flow 10.8% 23.2%
22nd		 18.8%
Accruals ratio -1.3% -4.3%
86th		 -5.4%
Sloan accruals ratio -1.7% -1.5%
48th		 -1.3%
Earnings quality score (0-1) 1.00 1.00
24th		 0.75

Dividends & buybacks

MeasureAIndustry medianIndustry percentileSector median
Dividend yield 0.6% 0.0%
86th		 0.0%
Dividend per share (TTM) $1.02 $0.00
83rd		 $0.00
Payout ratio (dividends / net income) 19.9% 0.0%
82nd		 0.0%
Dividends / FCF 19.9% 0.0%
89th		 0.0%
Dividend growth (YoY) 2.9% 5.0%
40th		 4.5%
Buyback yield 0.8% 0.9%
48th		 0.0%
Shareholder yield (dividends + buybacks) 1.4% 1.1%
55th		 0.0%
Share count change (YoY) -0.7% -0.7%
50th		 2.0%
Buybacks, last 5 years $2.4B $129.7M
72nd		 $0

Scores & forensic checks

MeasureAIndustry medianIndustry percentileSector median
IS score 71 50
86th		 46
IS profitability 74 36
79th		 22
IS growth 60 55
57th		 60
IS value 55 40
93rd		 39
IS momentum 82 72
71st		 67
IS risk (safety) 100 80
62nd		 80
IS quality 81 62
79th		 49
IS balance sheet 76 51
79th		 55
IS earnings quality 74 69
72nd		 56
IS cash flow 72 50
83rd		 41
Piotroski F-score (0-9) 7 6
59th		 5
Altman Z-score 4.9 3.4
66th		 3.2
Beneish M-score −2.45 −2.60
86th		 −2.62
Ohlson O-score −8.92 −8.12
28th		 −7.16
IS credit score 94 67
97th		 62

Per share

MeasureAIndustry medianIndustry percentileSector median
EPS, diluted (TTM) $5.09 $1.54
69th		 −$0.03
Book value per share $26.02 $17.72
59th		 $7.10
Tangible book per share $5.06 $0.32
69th		 $1.91
Revenue per share $26.05 $26.05
48th		 $9.38
FCF per share $5.07 $2.08
62nd		 $0.46
Operating cash flow per share $5.69 $3.59
62nd		 $0.93
Cash per share $6.21 $6.18
52nd		 $3.51

Size (TTM)

MeasureAIndustry medianIndustry percentileSector median
Market cap $48.8B $13.8B
90th		 $2.4B
Revenue $7.4B $2.5B
79th		 $770.2M
EBITDA $2.0B $438.4M
83rd		 $56.1M
Net income $1.4B $139.0M
93rd		 −$3.3M
Free cash flow $1.4B $268.0M
90th		 $41.2M
Total assets $14.0B $3.4B
76th		 $1.3B
Shareholders' equity $7.4B $1.5B
79th		 $568.4M
Employees 18,200 6,319
76th		 1,086

Insider transactions, last 6 months

Form 4 · most recent 12
DateInsiderTypeSharesPriceValueOwned after
2026-09-08Boehnlein Glenn S
Director
 Award / grant 817$146.85$119,976817
2026-09-04Dolsten Mikael
Director
 Open-market sale 634$151.38$95,9724,924
2026-06-26Kirkwood Jonah Prevost
Senior Vice President
 Tax withholding 30$136.01$4,08014,108
2026-06-03Mcdonnell Padraig
Director, President and CEO
 Tax withholding 418$137.40$57,43365,842
2026-05-29Dolsten Mikael
Director
 Open-market sale 1,600$135.42$216,6725,548
2026-05-19Buckner Michael Steven
Senior Vice President
 Award / grant 8,872——8,887
2026-05-08May Simon
Senior Vice President
 Tax withholding 368$115.62$42,54814,015

Shares acquired vs disposed, by month

acquired disposed · all Form 4 types
MarMayJunSep

By transaction type, 6 months

TypeDirectionFilingsSharesValue
Award / grantAcquired29,689$119,976
Open-market saleDisposed22,234$312,644
Tax withholdingDisposed3816$104,062
—Disposed40—
Awards, option exercises and tax withholding are compensation mechanics; open-market buys and sales are the discretionary ones.

Form 144 notices

12 months: 6 notices · 21,235 shares · $3.2M
FiledFilerShares proposedEst. proceeds
2026-09-04Dolsten Mikael634$95,972
2026-05-29Dolsten Mikael1,600$216,672
2025-12-01Dolsten Mikael2,600$389,510
2025-11-26Gonsalves Rodney3,000$464,956
A Form 144 is notice of a proposed sale, not a confirmed one.

Congress trades

12 months: House 1 trades (0 purchases) · Senate 0 (0 purchases)
TradedMemberChamberTypeAmountDisclosed
2026-01-29Ro KhannaHouseSale$1,001 - $15,0002026-02-10
2025-09-29Ro KhannaHousePurchase$1,001 - $15,0002025-10-03
2025-09-23Julie JohnsonHouseSale$1,001 - $15,0002026-08-06
2025-09-23Julie JohnsonHousePurchase$1,001 - $15,0002026-08-06
2024-05-03Tommy TubervilleSenateSale (Full)$1,001 - $15,0002024-06-14
2024-05-03Tommy TubervilleSenateSale (Full)$1,001 - $15,0002024-06-13
2024-05-03Thomas Hawley TubervilleSenateSale (Full)$1,001 - $15,0002024-06-13
2024-04-05Tommy TubervilleSenatePurchase$1,001 - $15,0002024-05-15
STOCK Act disclosures, in ranges, filed up to 45 days after the trade.

Largest 13F holders

Quarter to 2026-06-30, the latest most managers have filed
ManagerSharesValue% of shares out
BlackRock, Inc.25,599,001$3.4B9.08%
VANGUARD CAPITAL MANAGEMENT LLC18,449,861$2.5B6.54%
VANGUARD PORTFOLIO MANAGEMENT LLC14,442,441$1.9B5.12%
STATE STREET CORP12,854,230$1.7B4.56%
MASSACHUSETTS FINANCIAL SERVICES CO /MA/10,010,867$1.4B3.55%
T. Rowe Price Investment Management, Inc.7,756,921$1.0B2.75%
GEODE CAPITAL MANAGEMENT, LLC7,595,644$1.0B2.69%
WELLINGTON MANAGEMENT GROUP LLP7,454,686$990.2M2.64%
DEUTSCHE BANK AG\7,008,217$930.9M2.49%
Bank of New York Mellon Corp5,096,050$676.9M1.81%
FMR LLC5,076,167$674.3M1.80%
GOLDMAN SACHS GROUP INC4,707,720$625.3M1.67%
Pictet Asset Management Holding SA4,494,311$597.0M1.59%
NORGES BANK3,869,544$514.0M1.37%
STATE FARM MUTUAL AUTOMOBILE INSURANCE CO3,825,278$508.1M1.36%

Institutional ownership by quarter

2023-092026-0693.5%
% of shares held by 13F filers
2023-092026-061,126
Number of 13F filers holding

Holder changes by quarter

QuarterHoldersOwnershipNewIncreasedReducedClosed
2026-06-301,12693.5%14645535583
2026-03-311,07090.0%109402372159
2025-12-311,13990.9%19735937661
2025-09-301,03088.9%11535636771
2025-06-301,00190.5%118359363117
2025-03-311,01489.8%96339396140
2024-12-311,07189.6%14036937593
2024-09-301,04489.0%13435037184
2024-06-301,00490.1%9738134693
2024-03-311,01292.3%9837534670
2023-12-3199991.0%18531933981
2023-09-3091189.3%8731634690

Schedule 13D / 13G filers

FiledFormFiler% of classShares
2026-04-28SCHEDULE 13GVanguard Portfolio Management5.1%14,387,171
2026-03-26SCHEDULE 13G/AThe Vanguard Group0.0%0
2025-04-17SCHEDULE 13G/ABlackRock, Inc.8.3%23,626,346
2025-02-13SCHEDULE 13G/AMassachusetts Financial Services Company4.4%12,442,834
Required above 5% of a class; 13G is the passive form.

ETFs with the largest holding

ETFWeight in fundHolding value
VITSX0.07%$1.5B
VTI0.07%$1.5B
VTSAX0.07%$1.5B
VSMPX0.07%$1.5B
VOO0.07%$1.3B
VFFSX0.07%$1.3B

Share structure

Shares outstanding281,965,815
Float280,978,899
Free float99.6%

Income statement

Fiscal years, USD
FY2021FY2022FY2023FY2024FY2025
Revenue$6.3B$6.8B$6.8B$6.5B$6.9B
Cost of revenue$2.9B$3.1B$3.4B$3.0B$3.3B
Gross profit$3.4B$3.7B$3.5B$3.5B$3.6B
R&D$441.0M$467.0M$481.0M$479.0M$455.0M
SG&A$1.6B$1.6B$1.6B$1.5B$1.7B
Operating income$1.3B$1.6B$1.4B$1.5B$1.5B
EBITDA$1.8B$1.9B$1.7B$1.9B$1.8B
Pretax income$1.4B$1.5B$1.3B$1.5B$1.4B
Income tax$150.0M$250.0M$99.0M$232.0M$132.0M
Net income$1.2B$1.3B$1.2B$1.3B$1.3B
EPS, diluted$3.94$4.18$4.19$4.43$4.57
Diluted shares307.0M300.0M296.0M291.0M284.0M

Balance sheet

FY2021FY2022FY2023FY2024FY2025
Cash & short-term investments$1.6B$1.1B$1.6B$1.3B$1.8B
Receivables$1.2B$1.4B$1.3B$1.3B$1.5B
Inventory$830.0M$1.0B$1.0B$991.0M$1.0B
Total current assets$3.8B$3.8B$4.2B$4.0B$4.6B
PP&E, net$945.0M$1.1B$1.4B$2.0B$2.0B
Goodwill & intangibles$5.0B$4.8B$4.4B$5.0B$4.9B
Total assets$10.7B$10.5B$10.8B$11.8B$12.7B
Accounts payable$446.0M$580.0M$418.0M$540.0M$570.0M
Total current liabilities$1.7B$1.9B$1.6B$1.9B$2.3B
Long-term debt$2.7B$2.7B$2.7B$3.3B$3.0B
Total liabilities$5.3B$5.2B$4.9B$5.9B$6.0B
Shareholders' equity$5.4B$5.3B$5.8B$5.9B$6.7B

Cash flow statement

Outflows are negative
FY2021FY2022FY2023FY2024FY2025
Net income$1.2B$1.3B$1.2B$1.3B$434.0M
Depreciation & amortization$321.0M$317.0M$271.0M$257.0M$288.0M
Stock-based compensation$110.0M$125.0M$111.0M$129.0M$128.0M
Change in working capital−$102.0M−$478.0M−$116.0M$83.0M−$58.0M
Operating cash flow$1.5B$1.3B$1.8B$1.8B$1.6B
Capital expenditure−$189.0M−$291.0M−$298.0M−$378.0M−$407.0M
Free cash flow$1.3B$1.0B$1.5B$1.4B$1.2B
Investing cash flow−$749.0M−$338.0M−$310.0M−$1.3B−$394.0M
Net debt issued / repaid$356.0M$26.0M−$35.0M$637.0M−$41.0M
Buybacks−$788.0M−$1.1B−$575.0M−$1.1B−$425.0M
Dividends paid−$236.0M−$250.0M−$265.0M−$274.0M−$282.0M

Ratio history

Margins on the fiscal-year (TTM at Q4) basis; multiples at each year end
FY2021FY2022FY2023FY2024FY2025
Gross margin53.9%54.4%50.7%54.3%52.4%
Operating margin21.3%23.6%19.8%22.9%21.3%
Net margin19.1%18.3%18.1%19.8%18.8%
FCF margin20.5%14.9%21.6%21.1%16.6%
ROE23.6%23.5%22.2%22.0%20.6%
ROIC18.3%19.2%17.9%15.5%16.2%
ROA11.9%11.8%11.6%11.4%10.6%
Debt / equity0.510.520.470.610.50
Interest coverage17.8x18.9x15.1x16.6x13.8x
Current ratio2.222.032.612.091.96
Revenue growth+18.4%+8.4%−0.2%−4.7%+6.7%
EPS growth+71.6%+6.1%+0.6%+4.7%+3.6%
P/E at year end38.6x32.2x24.1x29.2x31.9x
EV / EBITDA at year end27.2x22.1x18.2x21.5x23.5x
FCF yield at year end2.78%2.53%4.94%3.65%2.77%
Dividend payout19.5%19.9%21.4%21.3%21.6%

Revenue by segment

FY2021FY2022FY2023FY2024FY2025
Life Sciences and Applied Markets$2.8B$4.0B$3.9B$3.2B$2.7B
Agilent CrossLab$2.2B$1.5B$1.6B$1.6B$2.9B
Diagnostics and Genomics$1.3B$1.4B$1.4B$1.7B—
Applied Markets————$1.3B

Revenue by region · FY2025

Americas$2.8B · 40%
Asia Pacific$2.2B · 32%
Europe$1.9B · 28%

Street estimates by fiscal year

Next report 2026-11-23 · consensus EPS $1.72 · these are analysts' numbers, not ours
Fiscal yearRevenue (mean)Revenue rangeEPS (mean)EPS rangeAnalystsP/E on mean EPS
2026$7.5B$7.5B – $7.5B$6.20$6.19 – $6.291227.9x
2027$8.0B$7.9B – $8.0B$6.74$6.51 – $6.971325.7x
2028$8.5B$8.3B – $8.8B$7.44$6.92 – $8.00723.2x

Reported vs expected, every quarter on file

ReportedEPS expectedEPS actualEPS surpriseRevenue expectedRevenue actualRevenue surprise
2026-08-26$1.49$1.62+8.7%$1.8B$1.9B+2.0%
2026-05-27$1.41$1.49+5.7%$1.8B$1.8B+2.0%
2026-02-25$1.37$1.36−0.7%$1.8B$1.8B−0.5%
2025-11-24$1.58$1.59+0.4%$1.8B$1.8B+0.4%
2025-08-27$1.37$1.370.0%$1.7B$1.7B+3.2%
2025-05-28$1.26$1.31+4.0%$1.6B$1.7B+2.5%
2025-02-26$1.28$1.31+2.3%$1.7B$1.7B+0.7%
2024-11-25$1.41$1.46+3.5%$1.7B$1.7B+1.7%
2024-08-21$1.26$1.32+4.8%$1.6B$1.6B+1.3%
2024-05-29$1.19$1.22+2.5%$1.6B$1.6B−0.6%
2024-02-27$1.22$1.29+5.7%$1.6B$1.7B+4.4%
2023-11-20$1.34$1.38+3.0%$1.6B$1.7B+6.4%
2023-08-15$1.37$1.43+4.4%$1.7B$1.7B−1.2%
2023-05-23$1.26$1.27+0.8%$1.7B$1.7B+2.6%
2023-02-28$1.30$1.37+5.4%$1.7B$1.8B+3.3%
2022-11-21$1.39$1.53+10.1%$1.8B$1.8B+5.1%
2022-08-16$1.20$1.34+11.7%$1.6B$1.7B+4.9%
2022-05-24$1.12$1.13+0.9%$1.6B$1.6B−0.6%
2022-02-22$1.18$1.21+2.5%$1.7B$1.7B+1.2%
2021-11-22$1.17$1.21+3.4%$1.5B$1.7B+13.6%
2021-08-17$0.99$1.10+11.1%$1.7B$1.6B−4.4%
2021-05-25$0.82$0.97+18.3%$1.7B$1.5B−12.6%
2021-02-16$0.89$1.06+19.1%$1.5B$1.5B+6.0%
2020-11-23$0.91$0.98+7.7%$1.8B$1.5B−18.4%

Off-exchange (dark pool) volume, weekly

FINRA ATS, $ billions · through the week of 2026-08-31 (FINRA publishes with a delay)
0.306-150.406-220.306-290.407-060.507-130.507-200.407-270.308-030.308-100.608-170.908-240.608-31
Week ofNotionalSharesTrades
2026-08-31$555.2M3,681,46779,755
2026-08-24$878.9M5,679,98395,663
2026-08-17$574.2M3,705,02277,137
2026-08-10$282.9M1,904,59056,541
2026-08-03$284.6M2,023,54657,880
2026-07-27$407.5M2,933,81162,836

Short-sale share of off-exchange volume

daily 20-day average
07-2310-1556.6%
DateShort shareShort volumeTotal volume
2026-10-1556.6%343,590606,768
2026-10-1460.5%587,564971,608
2026-10-1345.4%253,230558,178
2026-10-1242.6%301,066706,855
2026-10-0943.5%334,519768,617
2026-10-0830.9%464,4951,505,111
2026-10-0749.5%590,4061,193,931
2026-10-0646.6%378,828813,279
2026-10-0530.9%234,227757,296
2026-10-0237.6%267,856711,869
A daily flow measure from FINRA, not short interest.

Seasonality

Average return by calendar month
+1.1Jan-3.4Feb+1.2Mar+0.8Apr+1.0May+0.0Jun+1.2Jul+1.1Aug+0.7Sep-0.2Oct+4.5Nov+1.4Dec
MonthAvg returnUp yearsYears
Jan+1.1%50%20
Feb−3.4%40%20
Mar+1.2%57%21
Apr+0.8%55%20
May+1.0%50%20
Jun+0.0%45%20
Jul+1.2%60%20
Aug+1.1%55%20
Sep+0.7%55%20
Oct−0.2%50%20
Nov+4.5%85%20
Dec+1.4%55%20
History, not a forecast.

Indicators

as of 2026-10-16
RSI 1462.4
MFI51.0
ADX39.1
Stochastic %K / %D78.8 / 74.2
Williams %R-32.1
CCI96
TSI / signal29.1 / 29.2
Chaikin money flow0.18
ATR$4.58
Bollinger width8.3%
Volume vs 20-day avg0.56x
SupertrendUp

Moving averages and bands

level (price vs level)
SMA 20$170.41 (+1.5%)
SMA 50$158.84 (+8.9%)
SMA 200$134.46 (+28.6%)
EMA 21$168.16 (+2.9%)
EMA 50$159.48 (+8.5%)
EMA 200$140.83 (+22.8%)
Bollinger upper$177.45 (−2.5%)
Bollinger lower$163.37 (+5.9%)
Parabolic SAR$164.10 (+5.4%)
Open the live chart, 110+ indicators

About Agilent Technologies, Inc.

Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.

https://www.agilent.com

Key executives

NameTitlePayBorn
Padraig McDonnellChief Executive Officer, President & Director$2.6M1972
Simon MaySenior VP and President of Life Sciences & Diagnostics Markets Group$1.6M1973
Bret DiMarcoSpecial Advisor$1.2M1968
Michael BucknerSenior Vice President, Chief Legal Officer, & Secretary$1.2M—
Angelica RiemannSenior VP & President of Agilent CrossLab Group$1.1M1971
Rodney GonsalvesVice President of Finance$832,0801966
August SpechtSenior Vice President & Chief Technology Officer——
Frederick SchwarzSenior VP, Chief Strategy & Corporate Development Officer——

Executive pay, latest proxy

ExecutiveYearSalaryStock awardsIncentiveTotal
Padraig McDonnell President; Chief Executive Officer2025$1.1M$8.2M$1.4M$12.8M
Robert McMahon Former Senior Vice President; Former Chief Financial Officer2025$665,000$4.0M$0$5.5M
Simon May Senior Vice President, Agilent President Life Sciences and Diagnostics Market Group2025$635,385$1.8M$472,395$3.9M
Bret DiMarco Senior Vice President, Chief Legal Officer2025$679,808$2.0M$475,466$3.7M
Angelica Riemann Senior Vice President, Agilent President Agilent Cross-Lab Group2025$591,346$1.7M$520,454$3.2M
Rodney Gonsalves Vice President; Controller; Interim Chief Financial Officer2025$513,559$1.7M$291,638$2.7M

Employees

15k201816k201916k202017k202118k202218k202318k202418k2025

Dividends

Ex-dateAmountPaid
2026-10-06$0.2552026-10-28
2026-06-30$0.2552026-07-22
2026-03-31$0.2552026-04-22
2026-01-06$0.2552026-01-28
2025-09-30$0.2482025-10-22
2025-07-01$0.2482025-07-23
2025-04-01$0.2482025-04-23
2024-12-31$0.2482025-01-22

Moat model

None · Efficient Scale · 2026-07-31
Cost advantage30
Intangibles26
Switching costs12
Network effect55
Efficient scale95
Our component scores (0-100) and overall 38.0; a model of the business, not a call on the stock.
InsiderStreet reports findings from filings and market data. Nothing on this page is a recommendation to buy or sell.Every figure is computed in code · data as of 2026-10-17

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms